Compare BioNTech SE - ADR (BNTX) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Check Point Software Technologies Ltd — how do they compare? BioNTech SE - ADR trades at $92.5 (market cap $23.30B), while Check Point Software Technologies Ltd trades at $134.52 (market cap $13.20B). The key difference: BioNTech SE - ADR is the larger of the two by market cap. Which is the better fit depends on your goals.
| BNTX | CHKP | |
|---|---|---|
Market Cap | $23.30B | $13.20B |
Sector | Health | Technology |
52-Week High | $119.34 | $206.91 |
52-Week Low | $83.89 | $112.47 |
Enterprise Value | $6.60B | $12.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.12, down 0.73% on the day, amid weak COVID-19 vaccine demand and a net loss of $1.14 billion in 2025. The stock shows a bullish technical signal with support near $92 and resistance at $93, while fundamentals reveal a high P/E of 161.14 and negative profitability margins. Recent news highlights a CEO transition to Guido Oelkers and a lowered 2026 sales outlook due to softening vaccine revenue.
The outlook remains cautious with declining revenues and persistent losses, though a strong cash position of $16.78 billion supports its oncology pipeline development. Risks include execution challenges in shifting from COVID-19 dependence, while analyst consensus is bullish with a $121 price target, implying 31% upside from current levels.
Check Point Software Technologies (CHKP) trades at $129.29, showing modest daily gains of 0.13%. The stock faces bearish technical signals with resistance at $131 and support at $127. Fundamentally, CHKP maintains strong profitability with 37.93% net margins and consistent earnings beats, though revenue growth remains modest. Recent news highlights AI security opportunities and insider selling activity.
CHKP presents a mixed outlook with attractive valuation metrics (P/E 13.26) offset by technical weakness and competitive pressures. The 13.6% upside to consensus price target of $146.92 suggests potential, but investors must weigh strong cash flow generation against margin compression risks and slowing growth in the cybersecurity sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
